摘要
目的观察吡喃阿霉素(THP)联合预激方案治疗难治性急性髓系白血病(RAML)疗效。方法随机分成两组:治疗组22例,用THP联合预激方案(THP+LDAra-C+G-CSF)治疗。对照组23例,应用MAE方案治疗。结果治疗组1疗程完全缓解(CR)率为59.1%,总CR率为72.7%,总有效率为81.2%;对照组1个疗程CR率为39.1%,总CR率为47.8%,总有效率为52.7%。两组间差异有统计学意义(P﹤0.05〉。两组间毒副反应差异有统计学意义(P﹤0.05〉。结论THP联合预激方案治疗难治性急性髓细胞性白血病疗效好,不良反应小,可作为难治性急性髓细胞性白血病的补救治疗方案。
Objective To observe the effect of pirarubicin(THP) combined with priming regimen in treatment of refractory acute myeloblastic leukemia(RAML).Methods The patients were divided into two groups randomly.Treatment group(n=22),the patients were treated with THP combined with LDAra-C and G-CSF.Control group were treated with MAE regimen.Results Of the patients in the treatment group,complete remission(CR) rate after one treating cycle was 59.1%,the total CR rate was 72.7%,the total response rate was 81.2%.In the contrast,one treating cycle CR rate was 39.1%,the total CR rate was 47.8%,the total response rate was 52.7%.There were significantly statistic differences in CR rates、the total response rates and side effects in the two groups(p<0.05).Conclusion The THP combined with is a well-effective treatment regimen for patients with RAML,and the side effects were mild.
